- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
PMCPA found Moderna responsible for a senior employee’s policy articles and X reposts. Missing disclosure breached Clause 5.5 and high standards (5.1).…
Complaint alleged Evra ad and linked ‘Benefits’/‘Safety & tolerability’ pages omitted full indication and key risks/contraindications. Panel found no breach of Clauses…
Complaint alleged a COPD therapy review service was misclassified as Joint Working and that software, patient leaflets and consultation summaries weren’t certified.…
Two Alliance representatives raised litigation/medico-legal consequences during a promotional meeting about Eliquis amid cost-driven switching to Lixiana. The Panel found scaremongering and…
A pharmacist challenged a Lyrinel XL ad’s “Gets our vote” imagery. The Panel found the illustration exaggerated satisfaction by ignoring discontinuations and…
Teva challenged two Trinity-Chiesi clinical support service pharmacist forms implying increased use of Clenil Modulite. The Panel found the complaint was too…
AstraZeneca challenged Trinity-Chiesi’s Fostair cost comparison chart as incomplete and misleading versus Symbicort and Seretide. The Panel found the chart acceptable in…
Complaint about Lantus promotional leavepieces and a mailer. Issues included “24-hour efficacy” wording and a hypoglycaemia comparison based on pooled observational data.…
A GP complained about an unsolicited promotional email for MacroBid sent to his NHS email via an agency. The Panel and Appeal…
AstraZeneca self-reported an uncertified promotional email about Crestor sent to a dispensing practice. The email and attached slides lacked prescribing information and…
An oncologist complained about “magnetic words” enclosed with an Arimidex mailing. The Panel said it was a promotional aid, not relevant to…
A Lipitor mailer compared LDL-C lowering across statins but then implied only Lipitor/rosuvastatin/ezetimibe combos had outcomes evidence. Panel found this misleading and…
Bayer Schering was found to have promoted Xarelto (rivaroxaban) before UK authorisation via a UK congress exhibition panel and a JBJS “supplement”…
Roche admitted an Avastin journal ad ran in the BMJ before final ABPI certification due to a process misunderstanding. PMCPA ruled breaches…
A Cipralex letter omitted key details from a PCT newsletter about non-formulary status and infrequent specialist use, implying broader acceptance. PMCPA found…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.